TELIX PHARMACEUTICALS
Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of prostate, renal (kidney) and glioblastoma (brain) cancer.
TELIX PHARMACEUTICALS
Industry:
Biotechnology
Founded:
2015-11-01
Address:
Melbourne, Victoria, Australia
Country:
Australia
Website Url:
http://www.telixpharma.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
494.87 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Euro SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics Google Maps
Similar Organizations
Abogen Biosciences
Abogen Biosciences is a discovery stage biotechnology company focuses on developing nucleic acid-based RNA and DNA therapeutics.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Ribon Therapeutics
Ribon Therapeutics is a biotechnology company focused on the development of therapeutics treatments targeting stress support pathways.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2024-03-04 | ARTMS | ARTMS acquired by Telix Pharmaceuticals | N/A |
| 2024-02-09 | IsoTherapeutics Group | IsoTherapeutics Group acquired by Telix Pharmaceuticals | 13 M USD |
| 2023-11-13 | QSAM Biosciences | QSAM Biosciences acquired by Telix Pharmaceuticals | N/A |
| 2023-04-26 | Dedicaid | Dedicaid acquired by Telix Pharmaceuticals | N/A |
| 2022-11-14 | Optimal Tracer | Optimal Tracer acquired by Telix Pharmaceuticals | N/A |
| 2020-11-30 | TheraPharm | TheraPharm acquired by Telix Pharmaceuticals | 33 M AUD |
| 2018-11-26 | Advanced Nuclear Medicine Ingredients | Advanced Nuclear Medicine Ingredients acquired by Telix Pharmaceuticals | 5.15 M EUR |
| 2018-09-11 | Atlab Pharma | Atlab Pharma acquired by Telix Pharmaceuticals | N/A |
Investors List
Australian Government
Australian Government investment in Grant - Telix Pharmaceuticals
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2023-11-12 | Mauna Kea Technologies | Telix Pharmaceuticals investment in Post-IPO Equity - Mauna Kea Technologies | 6 M EUR |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-12-04 | Telix Announces Executive Leadership Appointments |
| 2022-07-11 | Telix Pharmaceuticals names CEO of U.S. operations |
| 2021-08-31 | Michael Didocha Joins Telix as Chief Financial Officer, Americas |
Official Site Inspections
http://www.telixpharma.com Semrush global rank: 795.5 K Semrush visits lastest month: 37.25 K
- Host name: 104.19.154.92
- IP address: 104.19.154.92
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Telix Pharmaceuticals"
Telix Pharmaceuticals - Crunchbase Company Profile
Contact Email [email protected] Telix Pharmaceuticals Ltd is a clinical-stage biotechnology company engaged in developing and commercializing molecularly-targeted radiation therapy to address the unmet needs in the management of …See details»
Board & Management - Telix Pharmaceuticals
Our mission is to help patients with cancer live longer with better quality livesSee details»
Investor Relations - Telix Pharmaceuticals Limited
Nov 4, 2024 Telix Pharmaceuticals Limited Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts.See details»
Our Company - Telix Pharmaceuticals
Many existing therapies for cancer and rare diseases are non-selective, impacting healthy tissue and vital organs while treating the disease. Our radiopharmaceuticals are designed to deliver …See details»
2023 Annual Report
Message from Chairman "Telix has built a strong foundation as a diversified business and demonstrated our ability to capture this opportunity. We have an extensive clinical-stage pipeline of first-in-class or best-in-class therapeutic …See details»
Company directory | 2023 Annual Report - Telix
Telix Pharmaceuticals Limited 55 Flemington Road North Melbourne VIC 3051 [email protected] www.telixpharma.com. Australian Business Number. 85 616 620 369. …See details»
Telix Pharmaceuticals CEO and Key Executive Team | Craft.co
Telix Pharmaceuticals's Managing Director & Group Chief Executive Officer is Christian Behrenbruch. Other executives include Darren Smith, Group Chief Financial Officer; Lena …See details»
Telix Pharmaceuticals - Craft
Oct 29, 2024 Telix Pharmaceuticals has 5 employees across 10 locations and $502.55 m in annual revenue in FY 2023. See insights on Telix Pharmaceuticals including office locations, …See details»
Telix Announces Reorganisation to Deliver on Strategic Priorities
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, news releases, …See details»
Telix Announces Executive Leadership Appointments - PR Newswire
MELBOURNE, Australia, Dec. 4, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and …See details»
Telix - Overview, News & Similar companies | ZoomInfo.com
Telix contact info: Phone number: +61 330933897 Website: www.telixpharma.com What does Telix do? Telix Pharmaceuticals headquartered in North Melbourne, Australia, is a …See details»
Investor Resources - Telix Pharmaceuticals Limited
Telix’s lead imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the U.S. Food and …See details»
Our performance, strategy and future prospects | 2023 Annual …
$502.5M Total Group revenue Up $342.4M from 2022 reflects a full year of commercial sales of Illuccix® $5.2M Net profit after tax Significantly improved from $104.1M loss in 2022 $23.9M …See details»
Telix Announces Reorganisation to Deliver on Strategic Priorities
Telix today announces new leadership appointments as part of an internal reorganisation to align its operations across four business units, reflecting its focus as a therapeutics-led …See details»
Telix Pharmaceuticals Limited Completes the Acquisition of …
Apr 11, 2024 The collaboration between ARTMS’ unparalleled team, its investors and founding members has resulted in a truly differentiated organization. Solomon Partners Securities LLC …See details»
Purpose, Mission & Values - Telix Pharmaceuticals
Recent legislative changes to the Corporations Act 2001 (Cth), which came into effect on 1 April 2022, mean there are new options available to shareholders as to how you elect to receive …See details»
Telix Pharmaceuticals Limited completes the acquisition of ARTMS, …
Apr 11, 2024 Visit www.telixpharma.com for further information about Telix, including details of the latest share price, announcements made to the ASX, investor and analyst presentations, …See details»
Release Details - ir.telixpharma.com
Oct 24, 2024 Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for TLX101-CDx (Pixclara®), an agent …See details»
Sustainability - Telix Pharmaceuticals
A copy of this Declaration may be obtained by emailing [email protected]. Telix is committed to conducting business with honesty and integrity. Telix takes all concerns related …See details»